TWST · Twist Bioscience Corp
Market Cap
$7.97B
Shares
62.71M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$127.22
Open$127.92
Day$125.88–130.00
52W close$25.31–153.10
Avg vol 30d1.7M
Short int12.1M · 19.2% float · 6.9d
Short vol31%
Last earningsAug 3, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 7 wks
filed Aug 3, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$431.80M
Trailing 12 months
Net income (TTM)
−$136.72M
Trailing 12 months
Revenue growth YoY
+23.2%
Year over year
Operating margin
-33.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.0%
Year over year · more shares
Price change (1Y)
+425.0%
Trailing year
Short interest
19.2%
Latest settlement · 6.9 days to cover
AI Brief
Q3 FY26 earnings call · Aug 3, 2026
Q3 FY26
TL;DR. Twist Bioscience reported record Q3 revenue of $118.4 million (up 23% YoY), raised full-year FY26 revenue guidance by $12M at the midpoint to $456–457M, and reiterated Q4 adjusted EBITDA breakeven, while expressing confidence in triple-digit order growth for AI-enabled drug discovery in FY27.
Bullish
- + Reported record Q3 revenue of $118.4M, up 23% YoY, marking the 14th consecutive quarter of sequential growth.
- + Raised FY26 total revenue guidance by $12M at the midpoint to $456–457M (~21% YoY growth).
- + Gross margin expanded 120 bps sequentially to 52.8%, with management targeting >52% for FY26 and >60% as the business matures.
- + DSPS revenue grew 39% YoY to $56.6M, driven by therapeutics revenue up 49% YoY to $40.4M, including strength in AI-enabled drug discovery.
- + Expects to meet or exceed triple-digit percentage AI-enabled drug discovery order growth in FY26 and to again deliver triple-digit growth in FY27 orders.
- + Reiterated expectation of Q4 FY26 adjusted EBITDA breakeven, with one-time Q3 employee transition costs expected to reduce Q4 OpEx by more than $5M.
Bearish
- − Q3 GAAP net loss widened to $35.1M ($0.56/share) versus prior-year net income of $20.4M, which had benefited from a $48.8M Atlas Data Storage gain.
- − Industry and applied revenue declined 7% YoY to $5.7M from $6.1M.
- − Cash, cash equivalents and short-term investments declined to $166.8M at quarter-end from $171.7M as of March 31, 2026.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+91%
above
Price vs 50-day avg
+13%
above
RSI (14)
51
neutral
MACD trend
Negative
52-week position
80%
mid-range
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+202%
trailing
YTD return
+301%
this year
Relative strength
+185%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $113 › 200d $67 — 50d above 200d
Institutional flow
Accumulating
+20% holders QoQ · +91 funds added
Insider flow
Distributing
Net -$6.8M over 90 days · 100% sells
Short interest
Falling
19.24% of float · ▼ -14.5% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
339 holders — near 3-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
Revenue growth
+20%
Y/Y
EPS growth
+64%
Y/Y
Free cash flow
$-75.6M
Balance sheet
$89.5M
net cash
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
6.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 3, 2026
full fiscal year 2026
Total revenue
Initiated
$456M – $457M
prior FY $376.57M
midpoint +21.2% Y/Y
Gross margin
Initiated
at least 52%
fourth quarter
Total revenue
$123M – $124M
prior qtr $118.38M
midpoint +4.3% QoQ
Prior guidance
period ended
· from the 8-K filed Aug 2, 2024
Total revenue
· fiscal year 2024
$310M – $311M
SynBio revenue
· fiscal year 2024
$121M
NGS revenue
· fiscal year 2024
$169M – $170M
Biopharma revenue
· fiscal year 2024
$20M
Gross margin
· fiscal 2024
42%
Capital expenditure
· fiscal year 2024
$13M
Total revenue
· fourth quarter of fiscal year 2024
$82M – $83M
Gross margin
· fourth quarter of fiscal year 2024
44%
Guided vs delivered
· last 5 settled
Total revenue
fiscal year 2024
guided $310M – $311M
$312.97M
Beat +0.8%
Total revenue
fourth quarter of fiscal year 2024
guided $82M – $83M
$84.71M
Beat +2.7%
Revenue
year 2022
guided $189M – $198M
$203.57M
Beat +5.2%
Total revenue
Fiscal 2021
guided $129M – $132M
$132.33M
Beat +1.4%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+91%
Bullish
Price vs 50-day avg
+13%
Bullish
RSI (14)
51
Neutral
MACD trend
Negative
Bearish
52-week position
80%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $113 › 200d $67 — 50d above 200d
Institutional flow
Accumulating
+20% holders QoQ · +91 funds added
Insider flow
Distributing
Net -$6.8M over 90 days · 100% sells
Short interest
Falling
19.24% of float · ▼ -14.5% MoM · 6.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
339 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $25
Now $127 · 80%
Range high $153
vs 200-day avg +91%
vs 50-day avg +13%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TWST
this stock
Twist Bioscience Corp
|
$7.97B | +301.1% | +20.3% | — | 19.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.40B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.67B | +1.2% | +20.8% | 19.6 | 2.5% |
|
ARGX
Argenx SE
|
$61.60B | +17.1% | — | — | 2.0% |
|
CSLLY
Csl Ltd
|
$57.41B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TWST | -1.2% | +1.5% | +202.4% | -8.5% | +301.1% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | 0.0% | +3.3% | +184.6% | -8.1% | +289.0% |
Key facts
CIK
1581280
CUSIP
90184D100
13F (30d)
155 filings
154 filers
Visit website
Investor relations